SARS-CoV-2 infection: physical plasma therapy on site

Please share the love.

Lower the viral load with local therapy

The SARS-CoV-2 coronavirus multiplies mainly in the upper respiratory tract. Therefore, among other things, the contagiousness is extremely high, even if the infected person shows no symptoms. The infectiousness of people who tested positive for SARS-CoV-2 is to be reduced by a new rapid local therapy of the mouth and throat with physical plasma. The drug is also said to slow the progression of the disease.

Researchers at the Leibniz Institute for Plasma Research and Technology eV (INP) in Greifswald, the Research Center Borstel, the Leibniz Lung Center (FZB) and the Leibniz Institute for Experimental Virology (HPI) in Hamburg are working under the project title “PlasmaplusCorona (PPC) – Plasma ”on a technical solution for the local treatment of SARS-CoV-2-infected airways.

Reduce infectiousness and prevent disease severity

The aim of the new research at the Leibniz Institute is to develop a plasma-based technology solution for the local treatment of viral infections of the respiratory tract. The result of the initiative should be a new medical product or process that shortens the duration of viral infections and makes infected people less contagious.

Early intervention.

Since SARS-CoV-2 multiplies mainly in the upper respiratory tract, it can become contagious before infected people show symptoms of the disease. According to the Leibniz Institute, an early reduction in the viral load in the mouth and nasopharynx of those affected should prevent further spread of the virus and possibly a severe course of COVID-19 in the infected.

Plasma used to treat respiratory infections

This is exactly what the researchers want to achieve. Short message from the Bulgarian Business Journal.